Skip to main content
OLIPASS CORPORATION logo

OLIPASS CORPORATION — Investor Relations & Filings

Ticker · 244460 ISIN · KR7244460002 KO Professional, scientific and technical activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country KR South Korea
Listing KO 244460

About OLIPASS CORPORATION

https://www.olipass.com/front/eng/index…

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 72% confidence The document is a Korean KRX disclosure titled “투자판단 관련 주요경영사항” (Material Matters Related to Investment Decisions) with details on contract extension and R&D fee receipt from Vanda Pharmaceuticals. It is neither a full financial report (10-K/IR), earnings release (ER), nor any of the other specific categories (board changes, financing, dividends, share transactions, etc.). It is a standalone regulatory announcement of a material event. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-03-26 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 75% confidence The document is a Korean stock exchange regulatory disclosure titled “투자판단 관련 주요경영사항,” describing receipt of R&D fees under a joint research agreement and a correction to a prior filing. It is a standalone material event announcement, not a financial report, earnings release, or other defined category. As it does not fit specialized types (e.g., earnings, M&A, dividends, etc.), it falls under the general “Regulatory Filings” fallback category.
2026-03-26 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 87% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항” (“Major management matters related to investment decisions”), reporting the receipt of R&D funding from a partner. It is an official regulatory announcement of a material business event. It does not constitute an annual or interim report, earnings release, capital change notice, or board management change. It best fits the fallback category for miscellaneous regulatory announcements that do not match more specific filing types: Regulatory Filings (RNS).
2026-03-26 Korean
[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결)
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory disclosure (“투자판단 관련 주요경영사항”) announcing a joint R&D contract and its extension with Vanda Pharmaceuticals. It is not a full financial report (Annual, Interim, or Earnings), nor is it a board change, share transaction, dividend notice, or merger/takeover document. It is simply a miscellaneous regulatory announcement of a material event. Therefore, it falls under the fallback category “Regulatory Filings (RNS).”
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a formal regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from the company Olipass. It provides specific financial data, audit opinions (including 'disclaimer of opinion'), and details regarding capital impairment and operating losses. While it contains audit-related information, it is a structured regulatory disclosure of the audit results rather than the full, multi-page audit report document itself. Therefore, it falls under the 'Audit Report / Information' category as it provides the core audit findings and opinions. FY 2025
2026-03-20 Korean
기타시장안내 ('25사업연도 감사의견 거절 관련 상장폐지 절차 미진행)
Regulatory Filings Classification · 95% confidence The document is a short regulatory notice (433 characters) issued by a stock exchange regarding the status of a company's delisting process following an 'opinion disclaimer' in the audit report. It does not contain the audit report itself, but rather provides a regulatory update on the legal and listing status of the company. As it pertains to the status of delisting procedures and regulatory compliance, it fits best under the general regulatory filing category.
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.